

# Structural property of soybean protein P34 and specific IgE response to recombinant P34 in patients with soybean allergy

HIDEYUKI MORITA<sup>1,2</sup>, HIDEO KANEKO<sup>1,2</sup>, HIDENORI OHNISHI<sup>1</sup>, ZENICHIRO KATO<sup>1</sup>, KAZUO KUBOTA<sup>1</sup>, TAKAHIRO YAMAMOTO<sup>1</sup>, EIKO MATSUI<sup>1</sup>, TAKAHIDE TERAMOTO<sup>1</sup>, TOSHIYUKI FUKAO<sup>1</sup>, KIMIKO KASAHARA<sup>1</sup> and NAOMI KONDO<sup>1</sup>

<sup>1</sup>Department of Pediatrics, Graduate School of Medicine, Gifu University; <sup>2</sup>Department of Pediatrics, Nagara Medical Center, Gifu, Japan

Received August 9, 2011; Accepted September 26, 2011

DOI: 10.3892/ijmm.2011.841

**Abstract.** Soybean allergy is one of the important food allergies because soybean is widely used in processed foods. P34 has been identified as the main allergen in soybeans. The main objective was to analyze the structural property of recombinant P34 and the P34 antigen-specific IgE response in soybean allergy using recombinant P34. Recombinant P34 was expressed by the BL21 (DE3) strain of *Escherichia coli*. Purified recombinant P34 showed oligomerization and binding to endotoxin. The binding of recombinant P34 to endotoxin was confirmed by LPS pull-down assay. High-density SDS treatment dissociated oligomeric recombinant P34 and removed endotoxin. Both native P34 and purified recombinant P34 showed almost identical structural properties as determined by circular dichroism analysis. We analyzed recombinant-P34-specific IgE antibodies by the ImmunoCAP System. In ImmunoCAP using recombinant P34, all sera from healthy controls were classified as negative. A correlation was found between the specific IgE antibodies to whole soybean and recombinant P34 ( $r=0.526$ ,  $P<0.05$ ). The sera from 3 of 9 (33%) patients with outgrown soybean allergy and 6 of 9 (66%) patients with soybean allergy were classified as positive. SDS-treated recombinant P34 retained its structure and biological activity. Recombinant P34 is a useful tool for the analysis of antigen-specific response in soybean allergy. It may be possible to develop a modified form of recombinant P34 for the diagnosis or treatment of soybean allergy using specific immunotherapy techniques.

## Introduction

Soybean is one of the main sources of protein in human nutrition (1,2), and soybean is used in an increasing number of products because of its health benefits (3,4). However, in the United States, approximately 0.4% of children are allergic to soybean and many infants must not be fed soybean-based formula and baby foods (5). Soybean-induced allergic symptoms may range from skin, gastrointestinal, or respiratory reactions to anaphylaxis (5,6). Although the primary treatment for food allergies is to avoid the causative agent, it is difficult to avoid soy protein because of its extensive use in prepared and processed foods.

There are more than 20 soybean proteins that cause allergies (7). Recently, it has been reported that Gly m 5 ( $\beta$ -conglycinin) and Gly m 6 cause severe allergic reactions in Europe (8). In other reports, three proteins, Gly m Bd 60k, Gly m Bd 30k (P34), and Gly m Bd 28k represent the main seed allergens in soybean-sensitive patients (9,10). P34 is the allergen most strongly and frequently recognized by the IgE antibodies in the sera of soybean-sensitive patients with atopic dermatitis (3,11). In several IgE binding studies, more than 65% of soybean allergic patients with atopic dermatitis exhibited an allergic response to P34 (11-14). P34 is regarded as the major, or immunodominant, soybean allergen and is a target allergen for producing low-allergen-content hypoallergenic soybean products (15-17). Moreover, P34 shares high sequence homologies with the main peanut allergen Ara h 1, the dust mite allergen Der p 1, cow's milk caseins, and papain (18-20). Thus, peanuts and soybeans contain common allergenic components and, for this reason, IgE antibodies to peanut proteins may cross-react with soybean proteins.

First, we tried to express recombinant P34 (rP34) in *Escherichia coli* using a previously reported method (21). However, recombinant proteins expressed in *E. coli* carry the risk of endotoxin contamination. Endotoxin causes false-positive results in biological-cell-based assays, such as the cell proliferation assay and must be removed particularly when evaluating allergen-stimulated T cell proliferation (22). The methods for removing endotoxin vary greatly and depend on the structure and characteristics of particular allergens (13,22,23).

---

*Correspondence to:* Dr Hideo Kaneko, Department of Pediatrics, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan  
E-mail: hideo@gifu-u.ac.jp

*Abbreviations:* CD, circular dichroism; DLS, dynamic light scattering; LST, lymphocyte stimulation test; rP34, recombinant P34

*Key words:* endotoxin, ImmunoCAP, recombinant P34, SDS, soybean allergy, specific IgE

On the other hand, for serological diagnosis of soybean allergy, specific IgE antibodies to soybean proteins can be detected using commercially available tests. However, these tests are unsatisfactory for the identification of patients with soybean allergy. Specific IgE antibodies to major allergens in other foods, such as omega-5 gliadin, are highly useful for the diagnosis of food allergies (24). The measurement of specific IgE antibodies to rP34 may be useful. Furthermore, for a precise serological diagnosis, a tertiary folded soluble recombinant allergen protein is necessary.

In this study, we expressed rP34 using an *E. coli* expression system for the evaluation of clinical manifestation. Our purified rP34 had almost identical structural properties to native P34. Furthermore, ImmunoCAP System using rP34 was carried out to analyze the specific IgE antibodies to P34 in patients with and without soybean allergy.

## Materials and methods

**Soybean extracts.** Soybean (Fukuyutaka) flakes from commercial sources were ground to a fine powder using pestle and mortar and extracted by incubation with 20 mmol sodium phosphate and 1 mmol sodium chloride (1:20 wt/vol, pH 7.2) overnight at 4°C. Soybean mRNA was obtained using an RNeasy Plant Mini kit (Qiagen). Reverse transcription was carried out using an RNasin ribonuclease inhibitor (Promega) and M-MLV reverse transcriptase (Invitrogen). The sense and antisense primers used for PCR were designed on the basis of the cDNA sequences: 5'-GATTCGATCGAAGGTCGTAAGAAAATGAAGAAGGAAC-3' for the sense primer and 5'-GCGGCCGCAAGAGGAGAGTGATCAACTCTTC-3' for the antisense primer. The resulting DNA fragment was purified using a Gene Clean kit, ligated to a pUC118 plasmid, and transformed into the *E. coli* strain JM109. The resulting plasmid, pUC118/P34, was digested with *Eco*RI and *Not*I, and the fragment containing the P34 gene was inserted into pET24b and expressed in *E. coli* BL21 (DE3). The initial expression, purification and refolding of rP34 were performed in accordance with the method of Babiker *et al* (21).

**Purification of histidine-tagged recombinant P34 using Ni Sepharose column.** rP34 was purified using a Ni Sepharose column (Ni Sepharose 6 Fast Flow, 5 ml, GE Healthcare). The bound protein was eluted with 20 ml of 100 mM phosphate buffer containing 500 mM imidazole, pH 7.4.

**Conformational change of recombinant P34.** To produce the monomeric form of P34, we used a previously reported method with modification (14). The homogeneity of rP34 was determined by dynamic light scattering (Dyna Pro-99, Proterion). The solution containing the oligomeric form of rP34 was treated with an equivalent volume of 4% SDS solution containing 10% 2-ME and heated at 98°C for 10 min. The solution was then loaded onto a Sephacryl S-200 column pre-equilibrated with 0.1 M sodium phosphate buffer (pH 7.6) containing 1% SDS and 10 mM 2-ME. The column was run at 20°C using the same buffer and the fractions containing P34 were collected.

**Endotoxin removal from recombinant P34.** Detoxi-Gel (Pierce) was used to remove contaminating endotoxin in

accordance with the manufacturer's instructions. The collected samples were dialyzed against 50 mM sodium phosphate buffer (pH 7.6) overnight at 4°C. The level of endotoxin was measured by a chromogenic limulus amoebocyte lysate assay (endotoxin single test; Wako Pure Chemical Industries). The collected sample was dialyzed against 50 mM sodium phosphate buffer (pH 7.6) overnight at 4°C to remove any remaining SDS and stored at -20°C.

Endotoxin was also removed by Triton X-114 phase separation, as described by Liu *et al* (25). Triton X-114 was added to rP34 to a final concentration of 1% and incubated for 30 min at 4°C with constant stirring, followed by a 10-min incubation at 37°C and centrifugation at 20,000 x g at 25°C for 10 min.

**N-terminal sequencing of recombinant P34.** After separation by SDS-PAGE for 1 h at 200 mA in 25 mM Tris, 192 mM glycine, and 10% methanol, the proteins were electroblotted onto a polyvinylidene difluoride membrane (Amersham Biosciences). The membrane was briefly stained with CBB R250 (Wako, Japan) and destained extensively in 45 and 90% methanol solutions containing 7% acetic acid. Amino acid sequence analysis of rP34 was carried out using an Edman degradation technique using a pulse liquid automatic sequencer (Model 491HT, Applied Biosystems).

**Circular dichroism (CD).** For SDS-treated proteins, SDS concentrations of 0, 1 and 4% (0,  $3.5 \times 10^{-2}$  and  $1.4 \times 10^{-1}$  M) were used. Optically clear solutions in phosphate buffer were used to record CD spectra (195–250 nm) in a 1 mm rectangular quartz cell (JASCO) using a CD spectrometer (JASCO). The secondary structure was determined by visual assessment of the spectra and using the computer program CDPPro. Native P34 was provided by Professor S. Nagaoka of Gifu University.

**Dynamic light scattering (DLS).** DLS was carried out using a DynaPro-99 molecular-sizing instrument equipped with a microsampler (Protein Solutions). rP34 samples containing 0, 1 and 4% SDS were used in the experiment. The DynaPro-99 instrument was operated in accordance with the DLS machine protocol to estimate the molecular weight of rP34. Data were analyzed using the Dynamics 5.0 software (Protein Solutions).

**LPS pull-down assay.** A pull-down assay of the recombinant protein using labeled LPS was carried out as previously described (26,27). Briefly, 10 µg of biotinylated LPS (Alexis Biochemicals) was absorbed onto 20 µl of streptavidin agarose (Vector Laboratories) and incubated with 10 µg of LPS-free rP34 at room temperature for 1 h. After washing with PBS containing 0.1% Triton X-100, the precipitated protein was detected by silver staining.

**Homology modeling of P34.** The 31 kDa cysteine protease SPE31 (PDB code, 2b1 m) was selected from a protein database (www.rcsb.org/pdb) as the most homologous template for P34. The structural modeling of P34 was performed using the MOE software (Chemical Computing Group, Inc.).

**Subjects.** Patients with a history of soybean allergy were selected as subjects of this study (Table I), and grouped on the basis of the results of the open challenge test or the accidental






Figure 3. Circular dichroism spectra of native P34 and recombinant P34 exposed to SDS. The secondary structures of both native and recombinant P34 after SDS treatment were estimated using a computer program (CDPro).

(Fig. 4). Analysis of the sequence alignments for P34 identified SPE31 as sharing 78% sequence identity (29). The overall structure of P34 contains two independent domains, namely, the L domain and R domain, which form a cleft. The major secondary structural part of the L domain forms the  $\beta$ -sheet and that of the R domain forms the  $\alpha$ -helix.

*Reactivity of IgE in sera from soybean allergic patients to rP34 examined by ImmunoCAP System.* A total of 31 sera (13 controls, 9 outgrown, and 9 patients with soybean allergy) were available for the present study. The levels of rP34-specific IgE antibodies in the sera from outgrown and allergic patients measured by ImmunoCAP System are shown in Table I. Among the 31 sera investigated, 9 were positive for the specific IgE antibodies to rP34 and 22 were negative. A correlation was found between specific IgE antibodies to soybean and rP34. The correlation value was 0.526 and  $P < 0.05$ . All sera from healthy controls were negative for the antibodies. Six of the 9 (66%) outgrown and 3 of the 9 (33%) allergic patients were also negative for the antibodies. The positive sera belonged to class 1 (4 sera), class 2 (3 sera) and class 3 (2 sera). No serum belonged to classes 4

to 6. Four of 5 patients with sera belonging to class 2 or 3 were not tolerant to soybean. The median concentrations of specific IgE antibodies to rP34 were 1.63 kUA/l (range, 0.35-5.00) in the allergic group and 0.50 kUA/l (range, 0.35-1.26) in the outgrown group.

**Discussion**

Recently, recombinant allergens have become available for diagnostic and therapeutic purposes (23,30,31). It is particularly important to evaluate T cell activation for diagnosis and specific immunotherapy using allergens. However, the use of recombinant antigens contaminated with endotoxin leads to nonspecific cytokine production and affects T cell proliferation, thereby masking any antigen-specific responses. In our previous study, we showed that endotoxin-free rP34 might be a useful tool for evaluation of soybean allergy (32). It is essential to remove endotoxin from recombinant proteins before using them in the analysis of antigen-specific responses.

During the processes of protein purification, we noted a strong affinity of rP34 to endotoxin derived from the host strain. In this study, we clearly showed the LPS binding ability of P34 by the LPS pull-down assay (Fig. 2). It is reported that P34 contains many hydrophobic residues and is, thus, insoluble in aqueous solutions (16). The structural model of rP34 (Fig. 4C) indicated that many of the hydrophobic residues (shown in yellow) are located superficially, and thus may contribute to the strong affinity of rP34 to endotoxin. On the other hand, DLS analysis showed that rP34 treated with 4% SDS had a molecular weight of 34.9 kDa, whereas non-SDS-treated rP34 had a molecular weight of 790 kDa, indicating that SDS treatment disrupted the rP34 oligomers. This finding was consistent with the finding of a previous study, in which Ogawa *et al* (14) isolated native P34 in its oligomeric form (>300 kDa). In our recent study and in this study, it was also possible that these SDS-induced conformational changes enabled the separation of endotoxin from rP34 (32). From this findings, we speculated that the oligomerization property of P34 may influence its affinity to endotoxin.

It was reported that P34 is a receptor of the glycolipid elicitor syringolide produced by *Pseudomonas syringae*




Figure 4. Structural model of recombinant P34. (A) Alignment of P34 and SPE31 amino acid sequences. P34 shares 78% amino acid sequence identity with SPE31. (B) Structural model of mature P34. (C) Distribution of hydrophobic residues on P34. The hydrophobic residues are shown in yellow.

Table I. Characteristics of outgrown subjects and soybean allergic subjects.

Patient	Gender	Age (years)	Symptoms caused by soybean intake	Total IgE (IU/ml)	ImmunoCAP values			
					Soybean		rP34	
					Class	kUA/l	Class	kUA/l
1	M	6	Outgrown	3,540	2	4.14	2	1.26
2	F	1	Outgrown	133	1	1.40	1	0.56
3	M	4	Outgrown	156	0	<0.35	0	<0.35
4	M	5	Outgrown	233	2	0.84	0	<0.35
5	M	4	Outgrown	108	2	1.07	0	<0.35
6	M	3	Outgrown	377	2	1.94	0	<0.35
7	F	2	Outgrown	426	2	2.14	0	<0.35
8	F	3	Outgrown	374	2	3.60	1	0.61
9	M	9	Outgrown	977	2	1.02	0	<0.35
10	M	1	Urticaria	>16,000	5	88.2	3	5.00
11	M	4	Wheeze, urticaria	1,960	4	20.9	2	1.13
12	M	2	Erythema	31	1	0.59	0	<0.35
13	F	1	Cough, urticaria	626	2	1.63	0	<0.35
14	F	1	Urticaria	23.2	0	<0.35	0	<0.35
15	M	6	Cough, urticaria	1,490	5	76.4	1	0.41
16	M	1	Wheeze, urticaria	2,460	3	9.31	3	3.61
17	M	2	Urticaria	1,850	6	>100	1	0.45
18	F	6	Wheeze, urticaria	>16,000	5	57.1	2	2.93

(29,33). This suggests that P34 plays an important role in plant defenses against bacteria. Endotoxin is also recognized as a glycolipid elicitor and can induce defense responses in rice cells, including reactive oxygen generation and defense-gene expression. Both endotoxin and syringolide have considerable similarities in their immunological roles as pathogen-associated molecular patterns (PAMPs) (34). This suggests that P34 also recognizes the endotoxin in soybean in a manner similar to that of the Toll-like receptor 4 (TLR-4), MD-2, and CD14 in the mammalian innate immune systems (34-36). It is of particular interest that a recent report showed that the LPS-binding protein Der p 2 which is one of the major allergens of house dust mites, modulates mouse TLR-4 signaling and is associated with atopic dermatitis (37). Trompette *et al* (37) suggested that lipid-binding proteins possess the intrinsic adjuvant activity that underlies the phenomenon of allergenicity. The endotoxin binding ability of P34 may also be associated with allergic reactions in humans through a similar mechanism.

A previous report has described the linear B cell epitope on P34 (13). However, the conformational B cell epitopes on P34 remain to be fully elucidated. It is desirable to maintain the three-dimensional structure of P34, both for accurate evaluation of T cell responses and for the elucidation of conformational epitopes. High-density SDS may cause conformational changes in proteins. In a previous report, CD analysis of soybean glycinin (11S) and  $\beta$ -conglycinin showed that SDS treatment increased both the  $\alpha$ -helical and unordered structures of both proteins at the expense of the  $\beta$ -sheet structure (38). In this case, the relatively low-density SDS treatment ( $2 \times 10^{-3}$  M) may have changed the conformation of these proteins. However, in the

present study, no significant changes in the secondary structure of P34 occurred after high-density SDS treatment. Estimation of the secondary structure from the recorded CD spectra indicated no significant differences between non-SDS-treated native P34 and SDS-treated rP34 (Fig. 3). This suggests that both of the proteins form a similar folding pattern. Both CD and DLS analyses indicated that rP34 retained its secondary structure even after high-density SDS treatment. Our purified rP34 is useful for the analysis of linear or tertiary epitopes because it retains the tertiary structure of its protein.

We established the method using the ImmunoCAP system with purified rP34 for the first time. Measurement of the concentration of specific IgE antibodies to rP34 is more useful than IgE Western blotting (data not shown). A correlation was found between specific IgE antibodies to soybean and rP34. Patient 16, whose serum with specific IgE antibody to soybean had a relatively low score of 3, showed severe allergic reactions within two hours after soybean ingestion. It is assumed that the allergic reaction in this patient was caused mainly by P34 in soybean. On the other hand, the finding that patients 15 and 17 showed a high score for their serum with specific IgE antibodies to soybean but a low score of 1 for specific IgE antibodies to rP34 may indicate an allergic reaction to soy protein other than P34. These results showed that the rP34 ImmunoCAP system we established could play a role as a soy allergic diagnostic tool or could indicate outgrown allergy.

In conclusion, our proposed new purification method for rP34 did not affect the tertiary protein structure. The strong affinity of P34 for endotoxin/LPS suggests that P34 may modulate the immunological responses underlying allergenicity.

Furthermore, the ImmunoCAP system using our purified rP34 that retains its tertiary structure may be useful for the identification of patients with soybean allergy or for the indication of outgrown allergy.

### Acknowledgements

We are grateful to Professor T. Ogawa of Kyoto University and S. Nagaoka of Gifu University for providing the anti-P34 antibody and native P34. This study was in part funded by the Research and Development Program for New Bio-industry Initiatives (2005-2009) of the Bio-oriented Technology Research Advancement Institution (BRAIN), Japan.

### References

1. Franck P, Moneret Vautrin DA, Dousset B, Kanny G, Nabet P, Guenard-Bilbaut L and Parisot L: The allergenicity of soybean-based products is modified by food technologies. *Int Arch Allergy Immunol* 128: 212-219, 2002.
2. Lusas EW and Riaz MN: Soy protein products: processing and use. *J Nutr* 125: 573-580, 1995.
3. Wilson S, Blaschek K and de Mejia E: Allergenic proteins in soybeans: Processing and reduction of P34 allergenicity. *Nutr Rev* 63: 47-58, 2005.
4. Herian AM, Taylor SL and Bush RK: Identification of soybean allergens by immunoblotting with sera from soy-allergic adults. *Int Arch Allergy Appl Immunol* 92: 193-198, 1990.
5. Savage JH, Kaeding AJ, Mastui EC and Wood RA: The natural history of soy allergy. *J Allergy Clin Immunol* 125: 683-686, 2010.
6. Herman E: Soybean allergenicity and suppression of the immunodominant allergen. *Crop Sci* 45: 462-467, 2005.
7. Babiker EE, Hiroyuki A, Matsudomi N, Iwata H, Ogawa T and Bando N: Effect of polysaccharide conjugation or transglutaminase treatment on the allergenicity and functional properties of soy protein. *J Agric Food Chem* 46: 866-871, 1998.
8. Holzhauser T, Wackermann O, Ballmer-Weber BK, Bindslev-Jensen C, Scibilia J, Perono-Garoffo L, Ustumi S, Poulsen LK and Vieths S: Soybean (Glycine max) allergy in Europe: Gly m 5 (beta-conglycinin) and Gly m 6 (glycinin) are potential diagnostic markers for severe allergic reactions to soy. *J Allergy Clin Immunol* 123: 452-458, 2009.
9. Herman EM, Helm RM, Jung R and Kinney AJ: Genetic modification removes an immunodominant allergen from soybean. *Plant Physiol* 132: 36-43, 2003.
10. Ogawa T, Samoto M and Takahashi K: Soybean allergens and hypoallergenic soybean products. *J Nutr Sci Vitaminol* 46: 271-279, 2000.
11. Ogawa T, Bando H, Tsuji H, Okajima K and Sasaoka K: Investigation of the IgE-binding proteins in soybeans by immunoblotting with the sera of the soybean-sensitive patients with atopic dermatitis. *J Nutr Sci Vitaminol (Tokyo)* 37: 555-565, 1991.
12. Helm RM, Cockrell G, Herman E, Burks AW, Sampson HA and Bannon GA: Cellular and molecular characterization of a major soybean allergen. *Int Arch Allergy Immunol* 117: 29-37, 1998.
13. Helm RM, Cockrell G, Connaughton C, West CM, Herman E, Sampson H, Bannon GA and Burks AW: Mutational analysis of the IgE-binding epitopes of P34/Gly m Bd 30K. *J Allergy Clin Immunol* 105: 378-384, 2000.
14. Ogawa T, Tsuji H, Bando N, Kitamura K, Zhu Y, Hirano H and Nishikawa K: Identification of the soybean allergenic protein, Gly m Bd 30K, with the soybean seed 34-kDa oil-body-associated protein. *Biosci Biotech Biochem* 57: 1030-1033, 1993.
15. Yaklich RW, Helm RM, Cookrell G and Herman EM: Analysis of the distribution of the major soybean seed allergens in a core collection of glycine max accessions. *Crop Sci* 39: 1444-1447, 1999.
16. Kalinski A, Weisemann JM, Matthews BF and Herman EM: Molecular cloning of a protein associated with soybean seed oil bodies that is similar to thiol proteases of the papain family. *J Biol Chem* 265: 13843-13848, 1990.
17. Morishita N, Kamiya K, Matsumoto T, Sakai S, Teshima R, Urisu A, Moriyama T, Ogawa T, Akiyama H and Morimatsu F: Reliable enzyme-linked immunosorbent assay for the determination of soybean proteins in processed foods. *J Agric Food Chem* 56: 6818-6824, 2008.
18. Sicherer SH, Sampson HA and Burks AW: Peanut and soy allergy: a clinical and therapeutic dilemma. *Allergy* 55: 515-521, 2000.
19. Eigenmann PA, Burks AW, Bannon GA and Sampson HA: Identification of unique peanut and soy allergens in sera adsorbed with cross-reacting antibodies. *J Allergy Clin Immunol* 98: 969-978, 1996.
20. Rozenfeld P, Docena GH, Anon MC and Fossati CA: Detection and identification of a soy protein component that cross-reacts with caseins from cow's milk. *Clin Exp Immunol* 130: 49-58, 2002.
21. Babiker EE, Azakami H, Ogawa T and Kato A: Immunological characterization of recombinant soy protein allergen produced by *Escherichia coli* expression system. *J Agric Food Chem* 48: 571-575, 2000.
22. Velickovic TC, Thunberg S, Polovic N, Neimert-Andersson T, Groulund H, Hage M and Gafvelin G: Low levels of endotoxin enhance allergen-stimulated proliferation and reduce the threshold for activation in human peripheral blood cells. *Int Arch Allergy Immunol* 146: 1-10, 2008.
23. Saarne T, Kaiser L, Gronlund H, Rasool O, Gafvelin G and Hansten H: Rational design of hypoallergens applied to the major cat allergen Fel d 1. *Clin Exp Allergy* 35: 657-663, 2005.
24. Matsuo H, Dahistrom J, Tanaka A, Kohno K, Takahashi H, Furumura M and Morita E: Sensitivity and specificity of recombinant  $\omega$ -5 gliadin-specific IgE measurement for the diagnosis of wheat-dependent exercise-induced anaphylaxis. *Allergy* 63: 233-236, 2008.
25. Liu S, Tobias R, McClure S, Styba G, Shi Q and Jackowski G: Removal of endotoxin from recombinant protein preparations. *Clin Biochem* 30: 455-463, 1997.
26. Visintin A, Latz E, Monks BG, Espevik T and Golenbock DT: Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to toll-like receptor-4 aggregation and signal transduction. *J Biol Chem* 278: 48313-48320, 2003.
27. Koraha J, Tsuneyoshi N, Kimoto M, Gauchat JF, Nakatake H and Fukudome K: Comparison of lipopolysaccharide-binding functions of CD14 and MD-2. *Clin Diagn Lab Immunol* 12: 1292-1297, 2005.
28. Tsuji H, Bando N, Kimoto M, Okada N and Ogawa T: Preparation and application of monoclonal antibodies for a sandwich enzyme-linked immunosorbent assay of the major soybean allergen, Gly m Bd 30K. *J Nutr Sci Vitaminol (Tokyo)* 39: 389-397, 1993.
29. Zhang M, Wei Z, Chang S, Teng M and Gong W: A novel member in the cysteine proteinase family. *J Mol Biol* 358: 97-105, 2006.
30. Satoh R, Koyano S, Takagi K, Nakamura R, Teshima R and Sawada J: Immunological characterization and mutational analysis of the recombinant protein BWp16, a major allergen in buckwheat. *Biol Pharm Bull* 31: 1079-1085, 2008.
31. Swoboda I, Bugajska-Schretter A, Linhart B, Verdino P, Keller W, Schulmeister U, Sperr WR, Valent P, Peltre G, Quirce S, Douladiris N, Papadopoulos NG, Valenta R and Spitzauer S: A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy. *J Immunol* 178: 6290-6296, 2007.
32. Morita H, Kaneko H, Ohnishi H, Kato Z and Kondo N: Antigen specific immune response to endotoxin-free recombinant P34. *Allergy* 66: 985-986, 2011.
33. Ji C, Boyd S, Slaymaker D, Okinaka Y, Takeuchi Y, Midland SL, Sims JJ, Herman E and Keen N: Characterization of a 34-kDa soybean binding protein for the syringolide elicitors. *Proc Natl Acad Sci USA* 95: 3306-3311, 1998.
34. Desaki Y, Miya A, Venkatesh B, Tsuyumu S, Yaname H, Kaku H, Minami E and Shibuya N: Bacterial lipopolysaccharides induce defense responses associated with programmed cell death in rice cells. *Plant Cell Physiol* 47: 1530-1540, 2006.
35. Hirata T, Osuga Y, Hirota Y, Koga K, Yoshino O, Harada M, Morimoto C, Yano T, Nishii O, Tsutsumi O and Taketani Y: Evidence for the presence of toll-like receptor 4 system in the human endometrium. *J Clin Endocrinol Metab* 90: 548-556, 2005.
36. Zhao J, Davis LC and Verpoorte R: Elicitor signal transduction leading to production of plant secondary metabolites. *Biotech Adv* 23: 283-333, 2005.
37. Trompette A, Divanovic S, Visintin A, Blanchard C, Hegde RS, Madan R, Thorne PS, Wills-Karp M, Gioannini TL, Weiss JP and Karp CL: Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. *Nature* 457: 585-589, 2009.
38. Clara Sze KW, Kshirsagar HH, Venkatachalam M and Sathe SK: A circular dichroism and fluorescence spectrometric assessment of effects of selected chemical denaturants on soybean (*Glycine max* L.) storage proteins glycinin (11S) and  $\beta$ -conglycinin (7S). *J Agric Food Chem* 55: 8745-8753, 2007.